L’objectif de ces travaux de thèse était de rechercher un potentiel effet inhibiteur de l’acide acétique endogène sur le métabolisme oxydo réductif de Saccharomyces cerevisiae, afin d’évaluer la pertinence d’une stratégie d’amélioration des capacités de production d’éthanol par la modulation de la synthèse de cet acide. Ces travaux devaient également permettre d’approfondir la compréhension des principaux facteurs commandant la synthèse de l’acide acétique et plus largement des acides organiques. La stratégie de modulation de la synthèse d’acide acétique mise en place reposait sur des approches microbiologique et génétique, consistant en l’ajout d’acide oléique et / ou de carnitine dans le milieu de culture ainsi que la surexpression du gène CIT2 ou la suppression du gène ALD6.Cette démarche a permis de montrer que, contrairement à la version exogène, l’acide acétique endogène ne présentait pas d’effet inhibiteur du métabolisme oxydo réductif de Saccharomyces cerevisiae ou qu’il était négligeable par rapport au stress éthanol. En outre, la modulation de la production de cet acide ne semble pas être une stratégie envisageable en vue de l’amélioration des capacités de production d’éthanol de cette levure, bien qu’une corrélation ait été observée entre les titres finaux de ces deux molécules.En outre, il a été montré que l’isoforme 6 de l’acétaldéhyde déshydrogénase (Ald6p) était essentiel pour assurer la croissance cellulaire normale ainsi que les mécanismes de résistance au stress éthanol dans ces conditions de culture. Plus largement, l’interrelation entre les différents isoformes ne paraissait pas aussi flexible qu’en anaérobiose. Saccharomyces cerevisiae semblait également présenter un métabolisme flexible en réponse à une modulation de la synthèse d’acide acétique. La voie des pentoses phosphates serait ainsi capable de prendre le relais de l’Ald6p pour assurer la régénération du NADPH cytosolique, bien que le flux à travers cette voie semble avoir été limité par le ratio NADP+ / NADPH. Enfin, les cellules paraissaient capables de réguler la synthèse de l’acétyl coA à partir d’acide acétique en réaction à une évolution des besoins anaboliques lors de la fin de la phase de croissance. Elles seraient toutefois incapables de pallier le manque d’acétyl coA suite à la suppression du gène ALD6. La modulation de la synthèse des acides pyruvique et succinique a également fait l’objet de discussions. / The aim of this work was to investigate a potential inhibitory effect of endogenous acetic acid on the oxido-reductive metabolism of Saccharomyces cerevisiae, to assess the relevance of a strategy based of the modulation of the synthesis of this acid, to improve ethanol production capacities. This work should also help to broaden the understanding of the main factors controlling the synthesis of acetic acid, and more generally organic acids. The strategy to modulate the synthesis of acetic acid was based on microbiological and genetic approaches, consisting in the addition of oleic acid and / or carnitine in the medium as well as the overexpression of the gene CIT2 or the deletion of the gene ALD6.This approach has shown that, contrary to exogenous version, endogenous acetic acid did not induce inhibitory effects on the oxido-reductive metabolism of Saccharomyces cerevisiae, or was negligible compared to stress caused by ethanol. Moreover, the modulation of the synthesis of this acid appear to be not an attractive strategy to improve ethanol production capacities of the yeast, although a correlation was observed between the end-culture titer of these two molecules.In addition, it has been shown that the isoform 6 of acetaldehyde dehydrogenase (Ald6p) was essential to ensure regular growth and mechanisms of ethanol stress resistance under these conditions of culture. More broadly, the interrelation between the different isoforms did not seem as flexible as under anaerobic conditions. Saccharomyces cerevisiae also seemed to have a flexible metabolism in response to a modulation of the synthesis of acetic acid. The pentose-phosphate way would be able to take over from Ald6p for regeneration of cytosolic NADPH, although the ratio NADP+ / NADPH seemed to lessen the flux through this pathway. Finally, the cells appeared to be able to regulate the synthesis of acetyl-CoA from acetic acid in response to changing in anabolic needs at the end of the growth phase. However, yeasts would be unable to overcome the lack of acetyl-CoA following the suppression of the gene ALD6. The modulation of the synthesis of pyruvic and succinic acids has also been discussed.

Submitted by Angela Maria de Oliveira (amolivei@uepg.br) on 2017-11-24T13:23:07Z No. of bitstreams: 2 license_rdf: 811 bytes, checksum: e39d27027a6cc9cb039ad269a5db8e34 (MD5) Lidiane Pescke Pereira.pdf: 897636 bytes, checksum: 92549067a59b73ac61dbce09ee1c1ee0 (MD5) / Made available in DSpace on 2017-11-24T13:23:07Z (GMT). No. of bitstreams: 2 license_rdf: 811 bytes, checksum: e39d27027a6cc9cb039ad269a5db8e34 (MD5) Lidiane Pescke Pereira.pdf: 897636 bytes, checksum: 92549067a59b73ac61dbce09ee1c1ee0 (MD5) Previous issue date: 2017-09-20 / Com o aumento da produtividade e da demanda nutricional pela fêmea suína, o uso de moduladores L-carnitina, L-arginina, cromo, somatotropina e ractopamina tem sido uma alternativa para melhorar os índices produtivos. Entretanto, a variabilidade nas informações e a complexidade dos estudos envolvendo o tema exige uma abordagem mais sistêmica. Objetivou-se por meio desta meta-análise determinar o efeito do uso de moduladores nutricionais no desempenho reprodutivo e das leitegadas de porcas em gestação e lactação. A base de dados utilizada incluiu 83 artigos publicados entre os anos de 1989 e 2017, totalizando 22.608 porcas em 534 tratamentos. Critérios foram estabelecidos para a seleção dos artigos: uso de moduladores nutricionais: L-carnitina, L-arginina, cromo, somatotropina e ractopamina; conter as variáveis corporais e reprodutivas de porcas gestantes e lactantes. A meta-análise envolveu as análises de heterogeneidade, gráfica, correlação, variância e de resíduos. Não houve correlação (P>0,05) entre o uso de moduladores nutricionais e as variáveis corporais das porcas. No estudo de correlações verificou-se que a suplementação com L-carnitina, L-arginina e cromo aumentam (>0,450; P<0,05) o peso do leitão ao nascer e número de leitões nascidos vivos e o peso dos leitões ao nascer. Já o uso de somatotropina aumenta o número de leitões desmamados (0,985; P<0,01). Não houve diferença significativa (P>0,05) entre as médias dos grupos dos tratamentos com L-carnitina, cromo, e somatotropina para o consumo de ração e condição corporal das porcas. O uso de ractopamina aumentou em 3,41 % (P<0,05) a espessura de toucinho ao parto. A suplementação com L-carnitina e cromo aumentaram em 2,30 % e 4,73 % (P<0,05) o número de leitões nascidos vivos, respectivamente. O uso da L-carnitina, arginina e somatotropina proporcionaram, em média, leitões mais pesados ao nascer em relação ao controle (1,48 vs. 1,43kg; P<0,05). A administração da somatotropina aumentou em 9,01 % (P<0,05) o número de leitões desmamados em relação ao controle. Os estudos sobre o uso de moduladores nutricionais encontrados na literatura são pouco explorados quanto a condição corporal e nutricional, o que impossibilita conclusões sobre o uso adequado destes aditivos para ajustes nutricionais em porcas gestantes e lactantes. Entretanto, os moduladores nutricionais L-carnitina, L-arginina, cromo e somatotropina podem melhorar o desempenho produtivo das porcas e de suas leitegadas. / The increase in productivity and nutritional demand by sows, the use of modulators L-carnitine, L-arginine, chromium, somatotropin and ractopamine has been an alternative to improve the productive indexes. However, the variability in information and the complexity of studies involving the subject requires a more systemic approach. The objective of this meta-analysis was to determine the effect of the use of nutritional modulators on the reproductive performance and litter of sows in gestation and lactation. The database used included 83 articles published between 1989 and 2017, totaling 22,608 sows in 534 treatments. Criteria were established for the selection of articles: use of nutritional modulators: L-carnitine, L-arginine, chromium, somatotropin and ractopamine; contain the body and reproductive variables of pregnant and lactating sows. The meta-analysis involved analyzes of heterogeneity, graph, correlation, variance and residuals. Don´t were significant correlations (P>0.05) between the body variables of the sows and nutritional modulators and their use. In correlation study, the L-carnitine, L-arginine and chromium supplementation increases (>0.450; P<0.05) the birth piglets weight and liveborn number. Somatotropin administration increased the weaner piglets number (0.985; P<0.01). There were no significant difference (P>0.05) between the means of groups with L-carnitine, chromium, and somatotropin for feed intake and body condition of the sows. Ractopamine use increased in 3.41% (P<0.05) the backfat thickness at farrowing. Supplementation with L-carnitine and chromium increased in 2.30 % e 4.73 % (P<0.05) the alive piglets number, respectively. The use of L-carnitine, L-arginine and somatotropin provided heavier piglets at birth in relation to control groups (1.48 vs. 1.43kg; P<0.05). Somatotropin administration increased in 9.01% (P<0.05) the of weaned piglets number in relation to control group. Studies on the use of nutritional modulators found in the literature are poorly explored in body and nutritional condition terms, which makes it impossible to reach conclusions about the proper use of these additives for nutritional adjustments in pregnant and lactating sows. However, the nutritional modulators L-carnitine, L-arginine, chromium and somatotropin can improve the productive performance of sows and their litters.

As acidemias D-2-hidroxiglutárica e L-2-hidroxiglutárica são duas distintas desordens neurometabólicas bioquimicamente caracterizadas por níveis aumentados dos ácidos D-2-hidroxiglutárico e L-2-hidroxiglutárico em tecidos e fluidos biológicos, respectivamente. Pacientes acometidos pela acidemia D-2-hidroxiglutárica são classificados em duas variantes, a D-2-hidroxiglutárica do tipo I ou a D-2-hidroxiglutárica do tipo II. A acidemia D-2-hidroxiglutárica do tipo I é causada por uma mutação no gene da D-2-hidroxiglutarato desidrogenase enquanto que a acidemia D-2-hidroxiglutárica do tipo II é causada por uma mutação de ganho de função no gene da isocitrato desidrogenase II. A acidemia L-2-hidroxiglutárica é causada por uma mutação no gene da L-2-hidroxiglutarato desidrogenase. Considerando que a fisiopatologia destas doenças não está totalmente elucidada e que muitos estudos têm demonstrado o envolvimento do estresse oxidativo em erros inatos do metabolismo, este trabalho tem por objetivo principal investigar parâmetros de estresse oxidativo e nitrativo na urina de pacientes com acidemia L-2-hidroxiglutárica e o dano ao DNA in vitro causado pelos ácidos acumulados em ambas as patologias, as acidemias D-2-hidroxiglutárica e L-2-hidroxiglutárica, bem como o efeito protetor da L-carnitina sobre o dano. Dessa forma, verificou-se que as concentrações de 50 μM do ácido D-2-hidroxiglutárico e 30 μM do ácido L-2-hidroxiglutárico induzem dano ao DNA e que concentrações de 30 μM e 150 μM de L-carnitina reduzem significativamente in vitro o dano ao DNA, comparado aos controles. Além disso, foram analisadas amostras de urina dos pacientes com acidemia L-2-hidroxiglutárica. Observou-se aumento significativo de espécies de guanina oxidadas, um marcador bioquímico de dano oxidativo ao DNA, bem como um aumento significativo da excreção de di-tirosina, indicando que os pacientes tem dano a proteínas. Entretanto, não houve diferença significativa nos níveis de isoprostanos urinários e nos níveis de espécies reativas do nitrogênio. Esses resultados sugerem, pelo menos em parte, dano oxidativo a proteínas e ao DNA e ressaltam o potencial antioxidante da L-carnitina como um promissor adjuvante no tratamento de pacientes afetados pelas acidemias L-2-hidroxiglutárica ou D-2-hidroxiglutárica. / D-2-hydroxyglutaric and L-2-hydroxyglutaric acidurias are two distinct neurometabolic disorders biochemically characterized by increased levels of D-2-hydroxyglutaric and L-2-hydroxyglutaric acids in biological fluids and tissues, respectively. Patients affected by D-2-hydroxyglutaric aciduria are classified into two variants, D-2-hydroxyglutaric aciduria type I or D-2-hydroxyglutaric aciduria type II. D-2-hydroxyglutaric aciduria type I is caused by mutation of D-2-hydroxyglutarate dehydrogenase gene while D-2-hydroxyglutaric aciduria type II is caused by a gain of function mutation in isocitrate dehydrogenase 2 gene. L-2-hydroxyglutaric aciduria is caused by mutation in the L-2-hydroxyglutarate dehydrogenase gene. Considering that the pathophysiology of these diseases is not fully understood and that many studies have been shown the involvement of oxidative stress in inborn errors of metabolism, the main objective of this work was investigate oxidative and nitrative stress parameters in the urine of L-2-hydroxyglutaric aciduria patients and to investigate the in vitro DNA damage caused by the accumulated acids of D-2-hydroxyglutaric and L-2-hydroxyglutaric acidurias as well as the protective effect of L-carnitine on this damage. It has been found that concentrations of 50 μM of D-2-hydroxyglutaric acid and 30 μM of L-2-hydroxyglutaric acid induce DNA damage and concentrations of 30 μM and 150 μM of L-carnitine significantly reduced the in vitro DNA damage compared to controls. In addition, urine samples from L-2-hydroxyglutaric aciduria patients were analyzed. It was observed a significant increase of oxidized guanine species, an oxidative DNA damage biomarker as well as a significant increase of urinary di-tyrosine level, indicating protein oxidative damage in the patients. However, there was no significant difference in the levels of urinary isoprostanes and reactive nitrogen species. These results suggest, at least in part, proteins and DNA oxidative damage and highlight the L-carnitine antioxidant potential as a promising adjuvant in the treatment of patients affected by L-2-hydroxyglutaric or D-2-hydroxyglutaric aciduria.

Newborn screening programs measure analyte levels in neonatal blood spots to identify individuals at high risk of disease. Carnitine and acylcarnitine levels are primary markers used in the detection of fatty acid oxidation disorders. These analytes may be influenced by certain pre/perinatal or newborn screening related factors. The primary objective of this study was to explore the association between these characteristics and levels of blood carnitines and acylcarnitines in the newborn population. The study was composed of two parts: a systematic review and a clinical database analysis of existing newborn screening data. The systematic review results suggested considerable variability across studies in the presence and directionality of associations between analyte levels and birth weight, gestational age, age at time of blood spot collection, type of sample, and storage time. Sex was not significantly associated with carnitine or acylcarnitine levels in neonatal blood. We identified a need to more fully investigate a potential interaction between gestational age and birth weight in regard to analyte levels. The secondary data analyses indicated a statistically significant relationship between analyte levels and all perinatal / infant and newborn screening related factors of interest, but effect sizes were generally small. The interaction between gestational age and birth weight was significant in all models; when further explored through graphical analysis with conditional means, extremely premature neonates stood out as having distinct analyte patterns in relation to birth weight. Variation in the ratio of total acylcarnitine to free carnitine was better accounted for by the perinatal and newborn factors than was variation in any individual carnitine or acylcarnitine, indicating that proportions of carnitine and acylcarnitines may be more important in understanding an individual’s metabolic functioning than individual analyte levels. A low proportion of variation was explained in all multivariate models, supporting the use of universal algorithms in newborn screening and suggesting the need for further large scale empirical research targeted at previously unaccounted for perinatal factors such as birth stress.

Newborn screening programs measure analyte levels in neonatal blood spots to identify individuals at high risk of disease. Carnitine and acylcarnitine levels are primary markers used in the detection of fatty acid oxidation disorders. These analytes may be influenced by certain pre/perinatal or newborn screening related factors. The primary objective of this study was to explore the association between these characteristics and levels of blood carnitines and acylcarnitines in the newborn population. The study was composed of two parts: a systematic review and a clinical database analysis of existing newborn screening data. The systematic review results suggested considerable variability across studies in the presence and directionality of associations between analyte levels and birth weight, gestational age, age at time of blood spot collection, type of sample, and storage time. Sex was not significantly associated with carnitine or acylcarnitine levels in neonatal blood. We identified a need to more fully investigate a potential interaction between gestational age and birth weight in regard to analyte levels. The secondary data analyses indicated a statistically significant relationship between analyte levels and all perinatal / infant and newborn screening related factors of interest, but effect sizes were generally small. The interaction between gestational age and birth weight was significant in all models; when further explored through graphical analysis with conditional means, extremely premature neonates stood out as having distinct analyte patterns in relation to birth weight. Variation in the ratio of total acylcarnitine to free carnitine was better accounted for by the perinatal and newborn factors than was variation in any individual carnitine or acylcarnitine, indicating that proportions of carnitine and acylcarnitines may be more important in understanding an individual’s metabolic functioning than individual analyte levels. A low proportion of variation was explained in all multivariate models, supporting the use of universal algorithms in newborn screening and suggesting the need for further large scale empirical research targeted at previously unaccounted for perinatal factors such as birth stress.

Knowledge on the precise effects of surplus glucose supply in dairy cows is limited by the lack of information on how intermediary metabolism adapts at different levels of glucose availability. Therefore, a gradual increase of glucose supply via intravenous glucose infusion was used in the present study to test the dose effect of surplus provision of glucose on the metabolic status and milk production of dairy cows. Furthermore, the effects of increasing levels of surplus glucose on mRNA expressions and activities of rate-limiting enzymes involved in hepatic gluconeogenesis were investigated. Based on a previous finding that a positive energy balance may decrease hepatic carnitine palmitoyltransferase (CPT) enzyme activity, it was also of interest whether skeletal muscle CPT activity is downregulated in a similar manner during positive energy balance. Twelve midlactating Holstein-Friesian dairy cows were continuously infused over a 28-d experimental period with either saline (SI group, six cows) or 40% glucose solutions (GI group, six cows). The infusion dose was calculated as a percentage of the daily energy (NEL) requirements by the animal, starting at 0% on d 0 and increasing gradually by 1.25%/d until a maximum dose of 30% was reached by d 24. Dose was then maintained at 30% NEL requirement for 5 d. No infusions were made between d 29-32. Liver and skeletal muscle biopsies were taken on d 0, 8, 16, 24, and 32. Body weight (BW) and back fat thickness (BFT) were recorded on biopsies days. Blood samples were taken every 2 d. In addition, blood samples over 24 h (6-h intervals) were taken the days before each biopsy. Milk and urine samples were taken on biopsies days. BW and BFT increased linearly with increasing glucose dose for GI cows. No differences were observed in the dry matter intake, milk energy output, and energy corrected milk yield between groups. However, milk protein percentage and yield increased linearly in the GI group. Only occasional increases in blood glucose and insulin concentrations were observed in blood samples taken at 1000 h every 2 d. However, during infusion dose of 30% NEL requirements on d 24, GI cows developed postprandial hyperglycemia associated with hyperinsulinemia, coinciding with glucosuria. The revised quantitative insulin sensitivity check index (RQUIKI) indicated linear development of insulin resistance for the GI treatment. GI decreased serum concentrations of beta-hydroxybutyrate (BHBA) and blood urea nitrogen and tended to decrease the serum concentration of non-esterified fatty acids (NEFA). Liver glycogen content increased, while glycogen content in skeletal muscle only tended to increase by GI. No significant changes were observed in the activities and relative mRNA expression levels of hepatic phosphoenolpyruvate carboxykinase and glucose 6-phospatase. The activity of fructose 1,6-bisphosphatase (FBPase) and relative mRNA expression levels of pyruvate carboxylase (PC) were decreased in the GI group but only during the high dose of glucose infusion. Hepatic CPT activity decreased with GI and remained decreased on d 32. The hepatic expression levels of CPT-1A and CPT-2 mRNA were not significantly altered but tended to reflect the changes in enzyme activity. No effect of glucose infusion was observed on skeletal muscle CPT activity. The aforementioned adaptations were reversed four days after the end of glucose infusions except for those of BW, BFT, and lipid metabolism (i.e. serum BHBA and NEFA concentrations, hepatic CPT activity). It is concluded that mid-lactation dairy cows on an energy-balanced diet direct intravenously infused glucose predominantly to body fat reserves but not to increased lactation performance. Cows rapidly adapted to increasing glucose supply but experienced dose-dependent development of insulin resistance corresponding with postprandial hyperglycemia/hyperinsulinemia and glucosuria at dosages equivalent to 30% NEL requirements. The catalytic capacity of key hepatic gluconeogenesis enzymes in mid-lactating dairy cows is not significantly affected by nutritionally relevant increases of glucose supply. Only very high dosages selectively suppress PC transcription and FBPase activity. Finally, it can be concluded that suppression of CPT activity by positive energy balance appears to be specific for the liver in midlactating dairy cows.

As acidemias D-2-hidroxiglutárica e L-2-hidroxiglutárica são duas distintas desordens neurometabólicas bioquimicamente caracterizadas por níveis aumentados dos ácidos D-2-hidroxiglutárico e L-2-hidroxiglutárico em tecidos e fluidos biológicos, respectivamente. Pacientes acometidos pela acidemia D-2-hidroxiglutárica são classificados em duas variantes, a D-2-hidroxiglutárica do tipo I ou a D-2-hidroxiglutárica do tipo II. A acidemia D-2-hidroxiglutárica do tipo I é causada por uma mutação no gene da D-2-hidroxiglutarato desidrogenase enquanto que a acidemia D-2-hidroxiglutárica do tipo II é causada por uma mutação de ganho de função no gene da isocitrato desidrogenase II. A acidemia L-2-hidroxiglutárica é causada por uma mutação no gene da L-2-hidroxiglutarato desidrogenase. Considerando que a fisiopatologia destas doenças não está totalmente elucidada e que muitos estudos têm demonstrado o envolvimento do estresse oxidativo em erros inatos do metabolismo, este trabalho tem por objetivo principal investigar parâmetros de estresse oxidativo e nitrativo na urina de pacientes com acidemia L-2-hidroxiglutárica e o dano ao DNA in vitro causado pelos ácidos acumulados em ambas as patologias, as acidemias D-2-hidroxiglutárica e L-2-hidroxiglutárica, bem como o efeito protetor da L-carnitina sobre o dano. Dessa forma, verificou-se que as concentrações de 50 μM do ácido D-2-hidroxiglutárico e 30 μM do ácido L-2-hidroxiglutárico induzem dano ao DNA e que concentrações de 30 μM e 150 μM de L-carnitina reduzem significativamente in vitro o dano ao DNA, comparado aos controles. Além disso, foram analisadas amostras de urina dos pacientes com acidemia L-2-hidroxiglutárica. Observou-se aumento significativo de espécies de guanina oxidadas, um marcador bioquímico de dano oxidativo ao DNA, bem como um aumento significativo da excreção de di-tirosina, indicando que os pacientes tem dano a proteínas. Entretanto, não houve diferença significativa nos níveis de isoprostanos urinários e nos níveis de espécies reativas do nitrogênio. Esses resultados sugerem, pelo menos em parte, dano oxidativo a proteínas e ao DNA e ressaltam o potencial antioxidante da L-carnitina como um promissor adjuvante no tratamento de pacientes afetados pelas acidemias L-2-hidroxiglutárica ou D-2-hidroxiglutárica. / D-2-hydroxyglutaric and L-2-hydroxyglutaric acidurias are two distinct neurometabolic disorders biochemically characterized by increased levels of D-2-hydroxyglutaric and L-2-hydroxyglutaric acids in biological fluids and tissues, respectively. Patients affected by D-2-hydroxyglutaric aciduria are classified into two variants, D-2-hydroxyglutaric aciduria type I or D-2-hydroxyglutaric aciduria type II. D-2-hydroxyglutaric aciduria type I is caused by mutation of D-2-hydroxyglutarate dehydrogenase gene while D-2-hydroxyglutaric aciduria type II is caused by a gain of function mutation in isocitrate dehydrogenase 2 gene. L-2-hydroxyglutaric aciduria is caused by mutation in the L-2-hydroxyglutarate dehydrogenase gene. Considering that the pathophysiology of these diseases is not fully understood and that many studies have been shown the involvement of oxidative stress in inborn errors of metabolism, the main objective of this work was investigate oxidative and nitrative stress parameters in the urine of L-2-hydroxyglutaric aciduria patients and to investigate the in vitro DNA damage caused by the accumulated acids of D-2-hydroxyglutaric and L-2-hydroxyglutaric acidurias as well as the protective effect of L-carnitine on this damage. It has been found that concentrations of 50 μM of D-2-hydroxyglutaric acid and 30 μM of L-2-hydroxyglutaric acid induce DNA damage and concentrations of 30 μM and 150 μM of L-carnitine significantly reduced the in vitro DNA damage compared to controls. In addition, urine samples from L-2-hydroxyglutaric aciduria patients were analyzed. It was observed a significant increase of oxidized guanine species, an oxidative DNA damage biomarker as well as a significant increase of urinary di-tyrosine level, indicating protein oxidative damage in the patients. However, there was no significant difference in the levels of urinary isoprostanes and reactive nitrogen species. These results suggest, at least in part, proteins and DNA oxidative damage and highlight the L-carnitine antioxidant potential as a promising adjuvant in the treatment of patients affected by L-2-hydroxyglutaric or D-2-hydroxyglutaric aciduria.

As acidemias D-2-hidroxiglutárica e L-2-hidroxiglutárica são duas distintas desordens neurometabólicas bioquimicamente caracterizadas por níveis aumentados dos ácidos D-2-hidroxiglutárico e L-2-hidroxiglutárico em tecidos e fluidos biológicos, respectivamente. Pacientes acometidos pela acidemia D-2-hidroxiglutárica são classificados em duas variantes, a D-2-hidroxiglutárica do tipo I ou a D-2-hidroxiglutárica do tipo II. A acidemia D-2-hidroxiglutárica do tipo I é causada por uma mutação no gene da D-2-hidroxiglutarato desidrogenase enquanto que a acidemia D-2-hidroxiglutárica do tipo II é causada por uma mutação de ganho de função no gene da isocitrato desidrogenase II. A acidemia L-2-hidroxiglutárica é causada por uma mutação no gene da L-2-hidroxiglutarato desidrogenase. Considerando que a fisiopatologia destas doenças não está totalmente elucidada e que muitos estudos têm demonstrado o envolvimento do estresse oxidativo em erros inatos do metabolismo, este trabalho tem por objetivo principal investigar parâmetros de estresse oxidativo e nitrativo na urina de pacientes com acidemia L-2-hidroxiglutárica e o dano ao DNA in vitro causado pelos ácidos acumulados em ambas as patologias, as acidemias D-2-hidroxiglutárica e L-2-hidroxiglutárica, bem como o efeito protetor da L-carnitina sobre o dano. Dessa forma, verificou-se que as concentrações de 50 μM do ácido D-2-hidroxiglutárico e 30 μM do ácido L-2-hidroxiglutárico induzem dano ao DNA e que concentrações de 30 μM e 150 μM de L-carnitina reduzem significativamente in vitro o dano ao DNA, comparado aos controles. Além disso, foram analisadas amostras de urina dos pacientes com acidemia L-2-hidroxiglutárica. Observou-se aumento significativo de espécies de guanina oxidadas, um marcador bioquímico de dano oxidativo ao DNA, bem como um aumento significativo da excreção de di-tirosina, indicando que os pacientes tem dano a proteínas. Entretanto, não houve diferença significativa nos níveis de isoprostanos urinários e nos níveis de espécies reativas do nitrogênio. Esses resultados sugerem, pelo menos em parte, dano oxidativo a proteínas e ao DNA e ressaltam o potencial antioxidante da L-carnitina como um promissor adjuvante no tratamento de pacientes afetados pelas acidemias L-2-hidroxiglutárica ou D-2-hidroxiglutárica. / D-2-hydroxyglutaric and L-2-hydroxyglutaric acidurias are two distinct neurometabolic disorders biochemically characterized by increased levels of D-2-hydroxyglutaric and L-2-hydroxyglutaric acids in biological fluids and tissues, respectively. Patients affected by D-2-hydroxyglutaric aciduria are classified into two variants, D-2-hydroxyglutaric aciduria type I or D-2-hydroxyglutaric aciduria type II. D-2-hydroxyglutaric aciduria type I is caused by mutation of D-2-hydroxyglutarate dehydrogenase gene while D-2-hydroxyglutaric aciduria type II is caused by a gain of function mutation in isocitrate dehydrogenase 2 gene. L-2-hydroxyglutaric aciduria is caused by mutation in the L-2-hydroxyglutarate dehydrogenase gene. Considering that the pathophysiology of these diseases is not fully understood and that many studies have been shown the involvement of oxidative stress in inborn errors of metabolism, the main objective of this work was investigate oxidative and nitrative stress parameters in the urine of L-2-hydroxyglutaric aciduria patients and to investigate the in vitro DNA damage caused by the accumulated acids of D-2-hydroxyglutaric and L-2-hydroxyglutaric acidurias as well as the protective effect of L-carnitine on this damage. It has been found that concentrations of 50 μM of D-2-hydroxyglutaric acid and 30 μM of L-2-hydroxyglutaric acid induce DNA damage and concentrations of 30 μM and 150 μM of L-carnitine significantly reduced the in vitro DNA damage compared to controls. In addition, urine samples from L-2-hydroxyglutaric aciduria patients were analyzed. It was observed a significant increase of oxidized guanine species, an oxidative DNA damage biomarker as well as a significant increase of urinary di-tyrosine level, indicating protein oxidative damage in the patients. However, there was no significant difference in the levels of urinary isoprostanes and reactive nitrogen species. These results suggest, at least in part, proteins and DNA oxidative damage and highlight the L-carnitine antioxidant potential as a promising adjuvant in the treatment of patients affected by L-2-hydroxyglutaric or D-2-hydroxyglutaric aciduria.

Submitted by Liliane Ferreira (ljuvencia30@gmail.com) on 2018-10-11T14:31:19Z No. of bitstreams: 2 Tese - Tiago Omar Diesel - 2018.pdf: 2037910 bytes, checksum: e5037a6e126e6597f8f92b2754602731 (MD5) license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5) / Approved for entry into archive by Luciana Ferreira (lucgeral@gmail.com) on 2018-10-15T11:00:19Z (GMT) No. of bitstreams: 2 Tese - Tiago Omar Diesel - 2018.pdf: 2037910 bytes, checksum: e5037a6e126e6597f8f92b2754602731 (MD5) license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5) / Made available in DSpace on 2018-10-15T11:00:19Z (GMT). No. of bitstreams: 2 Tese - Tiago Omar Diesel - 2018.pdf: 2037910 bytes, checksum: e5037a6e126e6597f8f92b2754602731 (MD5) license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5) Previous issue date: 2018-09-13 / Fundação de Amparo à Pesquisa do Estado de Goiás - FAPEG / Chemical delipidation has been used as an alternative to improve the cryotolerance of in vitro produced embryos (IVP). The aim of this study was evaluate the effect of L-carnitine (LC) on the development and survival of vitrified IVP bovine embryos by the Cryotop method in the first assay, and in the second trial the effect of LC and Forskolin on Cryotop cryopreserved embryos Experiment 1), or by modified slow freezing (Experiment 2), so mitochondrial activity, intracytoplasmic lipid (LI) content, cellular apoptosis (NCA) and hatching after heating were evaluated. In the first essay LC was used at the concentration of 0,6 mg/mL in maturation culture medium (IVM), embryo culture (IVC) and / or post-thawing (REC), in four treatments: without LC (Control), LC added to CIV (LCiv), LC to CIV + LC to REC (LCivR), and LC to MIV / CIV + LC to REC (LMivCR). The addition of LC increased the production of blastocysts in D7 by 28.6% (LCiv) and the amount of embryos grade I by 36.9% (LCivR), the re-expansion rate in 22,7% and hatching in 20.1% (LCiv), and mitochondrial activity was 1.9 times higher (P <0.001) (LCivR) than Control. The LI quantity was 29% lower in LCiv and LCivR and 50.2% in LMivCR compared Control (P <0.001). In the second experiment the embryos were cultured without addition of delipidators (Control), in the presence of 10μM of Forskolin added to the IVC in D5 (FORSK) or L-carnitine (0.6 mg / mL) added to the IVC and in post-thawing (LC). LC supplementation increased the production of blastocysts in D7 by 22.0% and grade I embryos by 30.1% (P <0.05), in relation to Control and FORSK. In Experiment 1, the re-expansion rate in LC increased (P <0.05) 28.9% in relation to FORSK. In Experiment 2, two Control treatments were used for slow freezing (Classic and Modified). Hatching after 48 hours was greater (P <0.05) in LC compared to FORSK and Classical and Modified Controls (77.5%, 41.9%, 40.5%, 40.8% respectively). In the LC treatment, there was a decrease (P <0.05) of 64.7% in the degenerate embryo rate in relation to the Classical Control. Treatment with delipidators reduced LI content (P <0.001) by 2.2 fold in FORSK and four times in the LC compared to Control. The addition of 0.6 mg / mL of L-carnitine to the culture medium and the post-thawing increased the rate of in vitro production of bovine embryos acting positively on mitochondrial potential, reducing the amount of intracellular lipids and cellular apoptosis and increasing cryotolerance of embryos submitted to the modified slow freezing protocol. / A delipidação química tem sido utilizada como alternativa para a melhoria da criotolerância em embriões produzidos in vitro (PIV). Este estudo foi realizado objetivando avaliar o efeito da Lcarnitina (LC) sobre o desenvolvimento e a sobrevivência de embriões bovinos PIV vitrificados pelo método Cryotop no primeiro ensaio, e no segundo ensaio o efeito comparado da LC e Forskolin em embriões criopreservados por Cryotop (Experimento 1), ou por congelamento lento modificado (Experimento 2). Para isto foram avaliadas a atividade mitocondrial, o conteúdo de lipídeos intracitoplasmático (LI), a apoptose celular e a eclosão após o aquecimento. No primeiro ensaio a LC foi utilizada na concentração de 0,6 mg/mL no meio para maturação (MIV), cultivo (CIV) e/ou recultivo embrionário (REC), em quatro tratamentos: sem LC (Controle), LC adicionado ao CIV (LCiv), LC ao CIV+LC ao REC (LCivR), e LC ao MIV/CIV+ LC ao REC (LMivCR). A adição de LC aumentou (P <0,05) a produção de blastocistos em D7 em 28,6% (LCiv), a quantidade de embriões grau I em 36,9% (LCivR), a taxa de re-expansão em 22,7%, a eclosão em 20,1% (LCiv) e a atividade mitocondrial foi 1,9 vezes maior (P <0,001) (LCivR) em relação ao Controle. A quantidade LI foi 29% menor em LCiv e LCivR e 50,2% em LMivCR comparado Controle (P <0,001). No segundo ensaio os embriões foram cultivados sem adição de delipidadores (Controle), na presença de 10µM de Forskolin adicionado ao CIV no D5 (FORSK) ou L-carnitina (0,6 mg/mL) adicionada ao CIV e ao recultivo (LC). A suplementação com LC aumentou a produção de blastocistos em D7 em 22,0% e de embriões grau I em 30,1% (P <0,05), em relação ao Controle e ao FORSK. No Experimento 1 a taxa de re-expansão no LC aumentou (P <0,05) 28,9% em relação ao FORSK. No Experimento 2 foram utilizados dois tratamentos Controle para congelamento lento (Clássico e Modificado). A eclosão após 48 horas foi maior (P < 0,05) no LC em comparação ao FORSK e aos Controles Clássico e Modificado (77,5%, 41,9%, 40,5%, 40,8% respectivamente). No tratamento LC foi observada diminuição (P < 0,05) de 64,7% na taxa de embriões degenerados em relação ao Controle Clássico. O tratamento com delipidadores reduziu o conteúdo de LI (P < 0,001) em 2,2 vezes em FORSK e quatro vezes no LC comparados ao Controle. A adição de 0,6 mg/mL de L-carnitina aos meios de cultivo e recultivo aumentou a taxa de produção in vitro de embriões bovinos atuando positivamente sobre a atividade mitocondrial, reduzindo a quantidade de lipídeos intracelulares e a apoptose e aumentando a criotolerância dos embriões submetidos ao protocolo de congelamento lento modificado.

Orientadores: Anibal E. Vercesi, Luciane Carla Alberici / Dissertação (mestrado) - Universidade Estadual de Campinas, Faculdade de Ciencias Medicaas / Made available in DSpace on 2018-08-15T19:15:54Z (GMT). No. of bitstreams: 1 Guardia_PaoloGadioliLa_M.pdf: 2017398 bytes, checksum: 71295ad7aacb6f016fb0abb80fd36bf9 (MD5) Previous issue date: 2010 / Resumo: Inibidores da 3-hidroxi-3-metilglutaril-CoA redutase (estatinas) são fármacos utilizados para diminuir os níveis plasmáticos de colesterol e são, geralmente, seguros e bem tolerados. Ocasionalmente esses fármacos induzem miotoxicidade, como miopatia e rabdomiólise, e hepatotoxicidade. Neste trabalho investigou-se o mecanismo, in vitro e in vivo, pelo qual as estatinas atuam sobre a respiração mitocondrial de biópsias de músculo esquelético e de fígado de ratos. A incubação (1 hora) de biópsias permeabilizadas de músculo sóleo (2-3 mg) com doses crescentes de sinvastatina reduziu a velocidade de respiração mitocondrial estimulada por ADP ou FCCP de forma dose-dependente e significativa (p<0,05). A inibição causada por 1 |iM de sinvastatina nas velocidades de respiração estimuladas por ADP e FCCP foi de respectivamente cerca de 25% e 27%. Em contraste, não houve alteração significativa na velocidade de respiração de repouso. O efeito de 1|iM de sinvastatina foi inibido pela incubação concomitante com 100 |uM de mevalonato (produto da enzima HMG-CoA redutase), ou 10 |JM de coenzima Q10 (um outro produto da via de síntese do colesterol). A redução na velocidade de respiração também foi inibida pela incubação concomitante com 1 mM de L-carnitina. A incubação com sinvastatina aumentou de forma significativa (p<0,05) a produção de lactato pelas biópsias musculares em cerca de 26%, efeito protegido pela incubação concomitante com mevalonato ou coenzima Q10 ou L-carnitina na mesma concentração descrita anteriormente. Por outro lado, esta mesma concentração de sinvastatina não provocou efeito algum sobre as velocidades de respiração de mitocôndrias isoladas de músculo de ratos. A incubação (1 hora) de biópsias hepáticas (2-3 mg) com doses crescentes de sinvastatina reduziu a respiração mitocondrial estimulada por ADP ou FCCP, sem alterar a respiração de repouso. Sinvastatina (5 uM) inibiu significativamente (p<0,05) a respiração estimulada por ADP e FCCP em cerca de 24% e 29% respectivamente. Esta inibição não foi sensível a 100 |iM de mevalonato ou 10 |iM de coenzima Q10 ou 1 mM de L-carnitina. Biópsias de músculo sóleo de ratos tratados durante 15 dias com 100 mg / kg (gavagem) de sinvastatina apresentaram velocidades de consumo de oxigênio reduzidas em todos os estados respiratórios. Este efeito foi inibido pela administração concomitante de L-carnitina 200 mg / kg (gavagem). / Abstract: 3-Hydroxy-3-methylglutaryl CoA reductase inhibitors (statins) are safe and well-tolerated therapeutic drugs, that occasionally induce myotoxicity such as myopathy and rhabdomyolysis, and hepatotocixity. Here, we investigated in vitro and in vivo the mechanisms of statin-induced toxicity on mitochondrial respiration of rat skeletal muscle and liver biopsies. One hour incubation of permeabilized soleus muscle biopsies (2-3 mg) with increasing doses of simvastatin (1 to 40 |iM) reduced ADP- or FCCP-stimulated mitochondrial respiration rate in a dose-dependent manner. The inhibition of ADP- or FCCP-stimulated mitochondrial respiration rate by simvastatin 1 |iM was 25% and 27%, respectively. No changes in rest respiration rate was observed. Simvastatin (1 |JM) inhibition of muscle respiration was prevented by coincubation with 100 |JM mevalonate, 10 |JM coenzyme Q10 or 1 mM L-carnitine. Simvastatin (1 |JM) also increased lactate production in muscle biopsies by 26%; this effect was prevented by the coincubation with mevalonate, coenzyme Q10 or L-carnitine. At the same concentration, simvastatin did not inhibit the respiration of isolated skeletal muscle mitochondria suggesting that simvastatin effect on mitochondrial respiration is not direct. Incubation (1 hour) of liver biopsies (2-3 mg) with increasing doses of simvastatin reduced ADP- or FCCP-stimulated mitochondrial respiration rate without changes in rest respiration rate. The lowest simvastatin concentration able to reduce liver biopsies respiration rates was 5 |JM, which promoted 24% and 29% inhibition in ADP- or FCCP-stimulated respiration rates, respectively. This was not modified by mevalonate, coenzyme Q10 or L-carnitine. Soleus muscle biopsies from rats treated during 15 days with simvastatin (100 mg/kg, p.o.) presented L-carnite sensitive inhibition of oxygen consumption rate in all respiratory states. / Mestrado / Medicina Experimental / Mestre em Fisiopatologia Médica